{"nctId":"NCT02563067","briefTitle":"Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.","startDateStruct":{"date":"2015-12-03","type":"ACTUAL"},"conditions":["Asthma"],"count":877,"armGroups":[{"label":"QAW039 150 mg","type":"EXPERIMENTAL","interventionNames":["Drug: QAW039"]},{"label":"QAW039 450 mg","type":"EXPERIMENTAL","interventionNames":["Drug: QAW039"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"QAW039","otherNames":[]},{"name":"QAW039","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Written informed consent.\n* Male and female patients aged ≥12 years.\n* A diagnosis of severe asthma, uncontrolled on GINA 4/5 asthma medication.\n* Evidence of airway reversibility or airway hyper- reactivity.\n* FEV1 ≤80% of the predicted normal value for patients aged ≥18 years; FEV1 of ≤90% for patients aged 12 to \\<18 years\n* An ACQ score ≥1.5\n* A history of 2 or more asthma exacerbations within the 12 months prior to entering the study.\n\nExclusion Criteria:\n\n* Use of other investigational drugs within 5 half-lives of study entry, or within 30 days, whichever is longer.\n* Subjects who have participated in another trial of QAW039.\n* A QTcF (Fridericia) ≥450 msec (male) or ≥460 msec (female).\n* History of malignancy with the exception of local basal cell carcinoma of the skin.\n* Pregnant or nursing (lactating) women.\n* Serious co-morbidities.\n* Patients on \\>20 mg of simvastatin, \\> 40 mg of atorvastatin, \\>40 mg of pravastatin, or \\>2 mg of pitavastatin.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation","description":"A severe asthma exacerbation is defined as treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days and hospitalization; or treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days and emergency department visit (greater than 24 hours\\*); or death due to asthma.\n\nA moderate asthma exacerbation is defined as treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days either as an outpatient or in emergency department visits (Emergency department visit less than or equal to 24 hours). The high eosinophils subpopulation consists of all patients with blood eosinophil count ≥ 250 cells/μL at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":null},{"groupId":"OG001","value":"0.76","spread":null},{"groupId":"OG002","value":"1.06","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for Participants 12 Years and Older (AQLQ+12) Score in High Eosinophils Subpopulation","description":"AQLQ is a 32-item instrument administered as a self-assessment. AQLQ+12 is a modified version of AQLQ developed to measure functional impairments of participants aged 12-70 years. It is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Participants were asked to recall their experiences during the last 2 weeks and respond to each question on a 7-point scale (1=severe impairment, 7=no impairment), where higher scores indicated \"better quality of life.\" Overall AQLQ+12 score is the mean of all 32 responses. The high eosinophils subpopulation consists of all patients with blood eosinophil count ≥ 250 cells/μL at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.73","spread":"0.061"},{"groupId":"OG001","value":"0.71","spread":"0.062"},{"groupId":"OG002","value":"0.58","spread":"0.062"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Asthma Control Questionnaire-5 (ACQ-5) Score in High Eosinophils Subpopulation","description":"The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma control of a participant. The five questions (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheeze) enquire about the frequency and/or severity of symptoms over the previous week. The response options for all these questions range from zero (no impairment/limitation) to six (total impairment/ limitation) scale. The ACQ-5 score is the average of the individual item scores and ranges from 0 to 6. Higher scores indicates worsening of condition. The high eosinophils subpopulation consists of all patients with blood eosinophil count ≥ 250 cells/μL at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.92","spread":"0.067"},{"groupId":"OG001","value":"-0.84","spread":"0.068"},{"groupId":"OG002","value":"-0.75","spread":"0.069"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Pre-dose Forced Expiratory Volume in 1 Second (FEV1) in High Eosinophils Subpopulation","description":"Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Baseline is defined as the last available FEV1 measurement taken prior to the first dose of randomized study drug. The high eosinophils subpopulation consists of all patients with blood eosinophil count ≥ 250 cells/μL at baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.192","spread":"0.0306"},{"groupId":"OG001","value":"0.162","spread":"0.0311"},{"groupId":"OG002","value":"0.124","spread":"0.0313"}]}]}]},{"type":"PRIMARY","title":"Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in Overall Population","description":"A severe asthma exacerbation is defined as treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days and hospitalization; or treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days and emergency department visit (greater than 24 hours\\*); or death due to asthma.\n\nA moderate asthma exacerbation is defined as treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days either as an outpatient or in emergency department visits (Emergency department visit less than or equal to 24 hours).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":null},{"groupId":"OG001","value":"0.70","spread":null},{"groupId":"OG002","value":"0.93","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for Participants 12 Years and Older (AQLQ+12) Score in Overall Population","description":"AQLQ is a 32-item instrument administered as a self-assessment. AQLQ+12 is a modified version of AQLQ developed to measure functional impairments of participants aged 12-70 years. It is divided into 4 domains: activity limitation, symptoms, emotional function, and environmental stimuli. Participants were asked to recall their experiences during the last 2 weeks and respond to each question on a 7-point scale (1=severe impairment, 7=no impairment), where higher scores indicated \"better quality of life.\" Overall AQLQ+12 score is the mean of all 32 responses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.62","spread":"0.050"},{"groupId":"OG001","value":"0.67","spread":"0.050"},{"groupId":"OG002","value":"0.55","spread":"0.051"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Asthma Control Questionnaire-5 (ACQ-5) Score in Overall Population","description":"The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma control of a participant. The five questions (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheeze) enquire about the frequency and/or severity of symptoms over the previous week. The response options for all these questions range from zero (no impairment/limitation) to six (total impairment/ limitation) scale. The ACQ-5 score is the average of the individual item scores and ranges from 0 to 6. Higher scores indicates worsening of condition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":"0.055"},{"groupId":"OG001","value":"-0.77","spread":"0.055"},{"groupId":"OG002","value":"-0.70","spread":"0.055"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 52 in Pre-dose Forced Expiratory Volume in 1 Second (FEV1) in Overall Population","description":"Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Baseline is defined as the last available FEV1 measurement taken prior to the first dose of randomized study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.153","spread":"0.0247"},{"groupId":"OG001","value":"0.164","spread":"0.0249"},{"groupId":"OG002","value":"0.103","spread":"0.0250"}]}]}]},{"type":"POST_HOC","title":"All Collected Deaths","description":"Total Deaths are presented from first dose of study treatment until discontinuation of trial, up to maximum duration of 56 weeks.\n\nDeaths on-treatment are presented from first dose of study treatment until last dose of study treatment plus 30 days, up to maximum duration of 56 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":296},"commonTop":["Asthma","Nasopharyngitis","Bronchitis","Viral upper respiratory tract infection","Headache"]}}}